Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
PET Imaging Reveals Synaptic Loss in Multiple Sclerosis Progression
Researchers at SNMMI 2026 unveiled a breakthrough SV2A PET imaging technique to measure spinal cord synaptic density and track multiple sclerosis.
FDA Approves Orally Disintegrating Cavhanza Tablets for Ph+ CML
Cycle Pharma's Cavhanza (nilotinib ODT) won FDA approval for Ph+ CML, allowing safe co-administration with PPIs and H2RA acid reducers.
Merck's Calderasib Wins FDA Breakthrough Therapy Tag for Lung Cancer
The FDA granted Breakthrough Therapy designation to Merck’s calderasib (MK-1084) plus Keytruda for first-line KRAS G12C-mutant metastatic NSCLC.
First-in-Class Mitochondria Cancer Drug Gamitrinib Enters Phase 1 Trial
In a new clinical trial evaluated at ASCO 2026, the first-in-class mitochondria-targeted cancer drug gamitrinib demonstrated strong safety profiles.
FDA vs EMA: Study Shows US Approves More Orphan Drugs for Cancer
A cross-sectional study reveals the US FDA approves more orphan drugs with specific cancer and pediatric indications compared to Europe’s EMA.
Landmark Study Stops Pancreatic Cancer Before It Starts With KRAS Drugs
A breakthrough preclinical study shows that experimental KRAS inhibitors can eliminate microscopic precancerous lesions, preventing pancreatic cancer.
Pfizer and Innovent Sign $10.5B Deal for New Cancer Drug Development
Pfizer and Innovent Biologics strike a $10.5 billion licensing deal to co-develop 12 early-stage cancer medications, including antibody-drug conjugates.
GSK’s Nucala Secures NICE Endorsement for Uncontrolled COPD Treatments
The UK's NICE recommends GSK's Nucala (mepolizumab) for patients with uncontrolled COPD, expanding its clinical use alongside standard of care therapies.
FDA Grants Fast Track Designation to Elunetirom for Bipolar Depression
Autobahn Therapeutics receives FDA Fast Track status for elunetirom, a novel CNS-TR agonist aimed at treating adjunctive bipolar depression and MDD.
AI in Clinical Trials: Trust and Regulatory Concerns Remain Top Barriers
A Pistoia Alliance poll reveals that trust and regulatory uncertainty are the biggest barriers to adopting artificial intelligence in clinical trials.
Atossa Presents Preclinical Breast Cancer Drug Data at ASCO 2026 Meeting
Atossa Therapeutics highlights promising preclinical data for (Z)-endoxifen in ESR1-mutant breast cancer models at ASCO 2026, alongside clinical updates.
Vitamin B12-Like Drug NO-Cbl Shows Promise in Preclinical Glioma Studies
A new preclinical study reveals NO-Cbl, a Vitamin B12-mimicking therapy, successfully targets glioblastoma cells and acts synergistically with chemotherapy.
2
3
4
5
6
7
8
9
10
